Neue Welthandelsrunde statt neuer Protektionismus

--

Бетатрон с разделенными управляющим и ускоряющим полями

Рассмотрены особенности построения и расчета электромагнитной системы индукционного циклического ускорителя с прямолинейными промежутками. Благодаря разделению управляющего и ускоряющего электромагнитных потоков такой ускоритель способен обеспечивать ускорение электронов до энергий свыше 300 МэВ при приемлемых массогабаритных параметрах. Приведена оригинальная конструкция ускорительного модуля. Работа подготовлена при поддержке Российского фонда фундаментальных исследований

Synthesis of carbocycles based on glycerol and alpha-oxoacids

It is demonstrated some synthetic ways for carbocyclic structures based on glycerol and α-oxoacids, such as glyoxylic and pyruvic acid. These compounds can be monomers for synthesis of biodegradable polymers. The relevance of this research is due to using cheap renewable resources in monomer and polymer synthesis. It was shown conditions of monomer synthesis, their purification and identification

Long-Term Outcome of Anti-Glomerular Basement Membrane Antibody Disease Treated with Immunoadsorption

<div><p>Background</p><p>Anti-glomerular basement membrane (GBM) antibody disease may lead to acute crescentic glomerulonephritis with poor renal prognosis. Current therapy favours plasma exchange (PE) for removal of pathogenic antibodies. Immunoadsorption (IAS) is superior to PE regarding efficiency of antibody-removal and safety. Apart from anecdotal data, there is no systemic analysis of the long-term effects of IAS on anti-GBM-disease and antibody kinetics.</p><p>Objective</p><p>To examine the long-term effect of high-frequency IAS combined with standard immunosuppression on patient and renal survival in patients with anti-GBM-disease and to quantify antibody removal and kinetics through IAS.</p><p>Design</p><p>Retrospective review of patients treated with IAS for anti-GBM-antibody disease confirmed by biopsy and/or anti-GBM-antibodies.</p><p>Setting</p><p>University Hospital of Vienna, Austria.</p><p>Participants</p><p>10 patients with anti-GBM-disease treated with IAS.</p><p>Measurements</p><p>Patient and renal survival, renal histology, anti-GBM-antibodies.</p><p>Results</p><p>Anti-GBM-antibodies were reduced by the first 9 IAS treatments (mean number of 23) to negative levels in all patients. Renal survival was 40% at diagnosis, 70% after the end of IAS, 63% after one year and 50% at the end of observation (mean 84 months, range 9 to 186). Dialysis dependency was successfully reversed in three of six patients. Patient survival was 90% at the end of observation.</p><p>Conclusion</p><p>IAS efficiently eliminates anti-GBM-antibodies suggesting non-inferiority to PE with regard to renal and patient survival. Hence IAS should be considered as a valuable treatment option for anti-GBM-disease, especially in patients presenting with a high percentage of crescents and dialysis dependency due to an unusual high proportion of responders.</p></div

Extracorporal treatment and concomitant immunosuppression.

<p>Extracorporal treatment and concomitant immunosuppression.</p

Renal function and patient survival.

<p>Renal function and patient survival.</p

Cumulative costs of immunoadsorption and plasma exchange.

<p>Circles and triangles depict earliest timepoints of adsorber change due to reduced adsorption capacity (every 25 treatments for Immunosorba, every 35 treatments for Globaffin).</p

Baseline characteristics of patients treated.

<p>Baseline characteristics of patients treated.</p